Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Schwimmer

Gastroenterology Palm Beach Gardens, FL Medical Doctor

NPI 1245641380 CMS profile 5700533

3401 Pga Blvd Ste 500, Palm Beach Gardens, FL 33410

Open in the dashboard

General payments

$24,282

421 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Schwimmer of Palm Beach Gardens, FL is reported in the CMS Open Payments database as having received $24,282 across 421 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,431 36
2024 General $1,631 50
2023 General $2,441 115
2022 General $2,277 107
2021 General $1,785 86
2020 General $590 25
2019 General $126 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Schwimmer
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Schwimmer were reported at $15,431. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Schwimmer Gastroenterology median Middle half National median
2019 $126 $417 $126–$1,100 $163
2020 $590 $224 $74–$624 $114
2021 $1,785 $352 $106–$1,054 $132
2022 $2,277 $448 $129–$1,270 $149
2023 $2,441 $533 $150–$1,390 $160
2024 $1,631 $605 $160–$1,606 $164
2025 $15,431 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $17,793 138 payments
  2. Janssen Biotech, Inc. $1,562 65 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $834 33 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $624 34 payments
  5. Celgene Corporation $417 21 payments
  6. QOL Medical, LLC $407 21 payments
  7. Intercept Pharmaceuticals, Inc. $288 12 payments
  8. Pfizer Inc. $250 13 payments
  9. Genzyme Corporation $220 8 payments
  10. Nestle HealthCare Nutrition Inc. $171 8 payments
  11. Other $1,717 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,775 7 payments
  2. Food and Beverage $9,603 401 payments
  3. Travel and Lodging $433 1 payment
  4. Education $389 7 payments
  5. Gift $81 5 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $8,514 11 payments
  2. RINVOQ $7,355 44 payments
  3. STELARA $1,258 55 payments
  4. SKYRIZI Immunology $895 30 payments
  5. ENTYVIO $706 26 payments
  6. TREMFYA $587 13 payments
  7. XIFAXAN $550 28 payments
  8. CREON $509 29 payments
  9. LINZESS $492 31 payments
  10. HUMIRA $420 20 payments
  11. Other $4,678 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

496

Median for Gastroenterology: 569

Drug cost

$651,280

Median for Gastroenterology: $104,976

Branded share of claims

40.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 13 $349,315
Humira(Cf) Pen Adalimumab Brand 26 $231,636
Creon Lipase/Protease/Amylase Brand 12 $33,010
Mounjaro Tirzepatide Brand 15 $16,019
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 40 $6,841
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 45 $6,514
Pantoprazole Sodium Generic 229 $4,265
Cholestyramine Cholestyramine (With Sugar) Brand 26 $1,339
Colestipol Hcl Generic 25 $1,125
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 12 $758

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$114,261

Medicare's payments for the services billed

Medicare patients

437

Average age 77

Services billed

2,338

236 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 48%
Chronic kidney disease 37%
Diabetes 31%
Depression 30%
Atrial fibrillation 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $384
$384 13 —
RINVOQ
  • AbbVie, Inc. $376
$376 — —
SKYRIZI
  • AbbVie, Inc. $276
$276 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $122
$122 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

421 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record